S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:IDRA

Idera Pharmaceuticals (IDRA) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.17
▼
$7.23
52-Week Range
N/A
Volume
21,870 shs
Average Volume
464,030 shs
Market Capitalization
$450.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

IDRA stock logo

About Idera Pharmaceuticals (NASDAQ:IDRA) Stock

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Receive IDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IDRA Stock News Headlines

April 26, 2023 | npr.org
Marginalia
March 17, 2023 | washingtonpost.com
A mysterious rift propels the story in ‘Take What You Need’
June 4, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
January 18, 2023 | finanznachrichten.de
Idera Pharmaceuticals, Inc.: Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook
January 17, 2023 | finance.yahoo.com
Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook
January 10, 2023 | msn.com
Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 4, 2023 | thestreet.com
Idera (IDRA) Stock Soars on GlaxoSmithKline Partnership
November 18, 2022 | finanznachrichten.de
Idera Pharmaceuticals, Inc.: Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
June 4, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
November 14, 2022 | finance.yahoo.com
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
September 29, 2022 | finance.yahoo.com
Idera Pharma Acquires Rare Disease Player, Names New CEO
September 28, 2022 | marketwatch.com
Idera Pharma Shares Rise Nearly 18% After Aceragen Acquisition
September 28, 2022 | finance.yahoo.com
Idera Pharmaceuticals Acquires Aceragen
September 27, 2022 | benzinga.com
Idera Pharmaceuticals Stock (NASDAQ:IDRA), Dividends
August 9, 2022 | finance.yahoo.com
Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results
May 17, 2022 | seekingalpha.com
Idera halts melanoma trial for cancer candidate after early positive results
May 17, 2022 | finance.yahoo.com
Why Are Idera Pharmaceuticals Shares Soaring Today
May 17, 2022 | finance.yahoo.com
Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC
May 5, 2022 | finance.yahoo.com
Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
March 31, 2022 | finance.yahoo.com
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
December 15, 2021 | msn.com
Idera Shares Fall After Early Tilsotolimod Data, Seeks Collaborating Partners For TLR9 Agonist
December 14, 2021 | finance.yahoo.com
Idera Pharmaceuticals Announces Tilsotolimod Updates
December 8, 2021 | chron.com
5 Penny Stocks To Buy According To Analysts & Targets Up To 341%
November 8, 2021 | finance.yahoo.com
Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
August 9, 2021 | finance.yahoo.com
Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
July 21, 2021 | nasdaq.com
Idera Pharmaceuticals, Inc. Common Stock (IDRA)
June 22, 2021 | msn.com
Why Idera Shares Are Skyrocketing Today
See More Headlines


IDRA Company Calendar

Last Earnings
11/08/2021
Today
6/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IDRA
CUSIP
N/A
CIK
861838
Web
www.iderapharma.com
Phone
(484) 348-1600
Fax
617-679-5592
Employees
32
Year Founded
1989

Profitability

EPS (Most Recent Fiscal Year)
($0.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$98.09 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-68.74%
Return on Assets
-34.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.56
Quick Ratio
1.56

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
0.29
Book Value
$0.56 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
62,355,000
Free Float
59,206,000
Market Cap
$450.52 million
Optionable
Optionable
Beta
1.25

Social Links


Key Executives

  • Mr. John J. Kirby CPAMr. John J. Kirby CPA (Age 50)
    Chief Financial Officer
    Comp: $477.41k
  • Mr. Bryant David LimMr. Bryant David Lim (Age 51)
    Chief Bus. Officer & Gen. Counsel
    Comp: $480.96k
  • Mr. John C. Taylor (Age 52)
    CEO & Director
  • Mr. Daniel Salain (Age 55)
    Chief Operating Officer
  • Mr. Andy Jordan (Age 75)
    Chief Strategy Officer
  • Dr. Carl Kraus M.D. (Age 53)
    Chief Medical Officer
  • Dr. Shah Rahimian M.D.
    Ph.D., Medical Director & Global Clinical Lead for Oncology
  • Dr. Joanna Caroline Horobin Ch.B (Age 67)
    M.B., Advisor
  • Dr. Sudhir Agrawal D.Phil. (Age 68)
    F.R.S.C., Scientific Advisor
  • Mr. Louis J. Arcudi III (Age 61)
    M.B.A., MBA, Adviser

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













IDRA Stock - Frequently Asked Questions

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced its earnings results on Monday, November, 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01.

When did Idera Pharmaceuticals' stock split?

Shares of Idera Pharmaceuticals split before market open on Friday, November 25th 2022. The 2-1 split was announced on Friday, November 25th 2022. The newly issued shares were issued to shareholders after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Vincent Milano's approval rating as Idera Pharmaceuticals' CEO?

7 employees have rated Idera Pharmaceuticals Chief Executive Officer Vincent Milano on Glassdoor.com. Vincent Milano has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Idera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Idera Pharmaceuticals investors own include Oasis Petroleum (OAS), BioCryst Pharmaceuticals (BCRX), Sorrento Therapeutics (SRNE), Novavax (NVAX), Dynavax Technologies (DVAX), Proteostasis Therapeutics (PTI), Geron (GERN), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO) and Anavex Life Sciences (AVXL).

What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

Who are Idera Pharmaceuticals' major shareholders?

Idera Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include Bryant David Lim, Daniel B Soland, Elizabeth Ann Tarka, Invest Corp Pillar, John J Kirby, John J Kirby, Michael R Dougherty and Vincent Milano.
View institutional ownership trends.

How much money does Idera Pharmaceuticals make?

Idera Pharmaceuticals (NASDAQ:IDRA) has a market capitalization of $0.00. The biotechnology company earns $98.09 million in net income (profit) each year or ($0.32) on an earnings per share basis.

How can I contact Idera Pharmaceuticals?

Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The official website for the company is www.iderapharma.com. The biotechnology company can be reached via phone at (484) 348-1600, via email at jconwell@iderapharma.com, or via fax at 617-679-5592.

This page (NASDAQ:IDRA) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -